DNTH Stock Forecast 2025-2026
Distance to DNTH Price Targets
DNTH Price Momentum
10 Quality Stocks Worth Considering Now
Researching Magenta Therapeutics (DNTH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DNTH and similar high-potential opportunities.
Latest DNTH Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, DNTH has a bullish consensus with a median price target of $52.00 (ranging from $36.00 to $84.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $21.23, the median forecast implies a 144.9% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 295.7% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 69.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNTH Analyst Ratings
DNTH Price Target Range
Latest DNTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $84.00 |
| Mar 12, 2025 | Wedbush | Laura Chico | Outperform | Reiterates | $36.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $40.00 |
| Dec 20, 2024 | TD Cowen | Yaron Werber | Buy | Initiates | $0.00 |
| Nov 11, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $52.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $40.00 |
| Nov 8, 2024 | Raymond James | Steven Seedhouse | Outperform | Maintains | $56.00 |
| Oct 3, 2024 | Oppenheimer | Leland Gershell | Outperform | Initiates | $48.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $40.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $40.00 |
| Aug 9, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $36.00 |
| Jul 26, 2024 | Baird | Joel Beatty | Outperform | Initiates | $58.00 |
| Jun 27, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Initiates | $0.00 |
| May 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $40.00 |
| May 10, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $38.00 |
| Apr 18, 2024 | Raymond James | Steven Seedhouse | Outperform | Maintains | $51.00 |
| Mar 22, 2024 | Jefferies | Maury Raycroft | Buy | Maintains | $39.00 |
| Mar 22, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $33.00 |
| Feb 15, 2024 | Stifel | Alex Thompson | Buy | Initiates | $44.00 |
| Jan 26, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $24.00 |
Dianthus Therapeutics Inc. (DNTH) Competitors
The following stocks are similar to Magenta Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dianthus Therapeutics Inc. (DNTH) Financial Data
Dianthus Therapeutics Inc. has a market capitalization of $692.63M with a P/E ratio of 3.3x. The company generates $6.24M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +190.2% quarter-over-quarter, while maintaining an operating margin of -2,406.9% and return on equity of -32.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Dianthus Therapeutics Inc. (DNTH) Business Model
About Dianthus Therapeutics Inc.
Develops precision medicines for autoimmune diseases.
The company generates revenue through the discovery and development of monoclonal antibodies that target severe autoimmune and inflammatory diseases. By focusing on innovative therapies that restore immune system function, Dianthus Therapeutics aims to bring next-generation treatment options to market through strategic collaborations and research partnerships.
Dianthus Therapeutics is positioned within the biopharmaceutical sector and emphasizes addressing unmet medical needs, which may transform current standards of care and improve patient outcomes globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
78
CEO
Mr. Marino Garcia M.B.A.
Country
United States
IPO Year
2018
Website
dianthustx.comDianthus Therapeutics Inc. (DNTH) Latest News & Analysis
Latest News
Dianthus Therapeutics, Inc. (DNTH) experienced a share price increase with above-average trading volume, but earnings estimate revisions indicate potential weakness ahead.
Dianthus Therapeutics' share price surge on high volume may indicate short-term interest, but stagnant earnings estimates could signal potential future weakness, affecting investor confidence.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
1 month agoDianthus Therapeutics (Nasdaq: DNTH) is conducting multiple trials for DNTH103, with top-line results expected in 2H'25 and 2H'26. The company has $357 million in cash, funding operations into 2H'27.
Ongoing clinical trials for DNTH103 in multiple conditions could lead to significant advancements in treatment, impacting future revenue potential. Strong cash reserves extend operational runway.
Dianthus Therapeutics reported a Q3 loss of $0.81 per share, better than the estimated loss of $0.85, but wider than the $0.71 loss per share from the previous year.
Dianthus Therapeutics' smaller-than-expected loss indicates potential operational improvements, which may boost investor confidence and impact stock performance positively.
Mr. King launched the first approved biologic and C5 complement inhibitor for Myasthenia Gravis, establishing a foundation for Alexion's multi-billion dollar C5 franchise.
The launch of a biologic and C5 inhibitor in Myasthenia Gravis positions Alexion for significant revenue growth, solidifying its market leadership and potential for future innovations.
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) will participate in upcoming investor conferences to discuss its advances in antibody complement therapeutics for severe autoimmune diseases.
Dianthus Therapeutics' participation in investor conferences may signal increased visibility and potential investor interest, impacting stock performance and market perception of the company's pipeline.
Dianthus Therapeutics (Nasdaq: DNTH) will present at healthcare investor conferences in February, focusing on antibody complement therapeutics for severe autoimmune diseases.
Dianthus Therapeutics' participation in investor conferences indicates potential for increased visibility and interest in its therapeutic developments, which could impact stock performance and investor sentiment.
Frequently Asked Questions About DNTH Stock
What is Dianthus Therapeutics Inc.'s (DNTH) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Dianthus Therapeutics Inc. (DNTH) has a median price target of $52.00. The highest price target is $84.00 and the lowest is $36.00.
Is DNTH stock a good investment in 2025?
According to current analyst ratings, DNTH has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNTH stock?
Wall Street analysts predict DNTH stock could reach $52.00 in the next 12 months. This represents a 144.9% increase from the current price of $21.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dianthus Therapeutics Inc.'s business model?
The company generates revenue through the discovery and development of monoclonal antibodies that target severe autoimmune and inflammatory diseases. By focusing on innovative therapies that restore immune system function, Dianthus Therapeutics aims to bring next-generation treatment options to market through strategic collaborations and research partnerships.
What is the highest forecasted price for DNTH Dianthus Therapeutics Inc.?
The highest price target for DNTH is $84.00 from Yatin Suneja at Guggenheim, which represents a 295.7% increase from the current price of $21.23.
What is the lowest forecasted price for DNTH Dianthus Therapeutics Inc.?
The lowest price target for DNTH is $36.00 from Laura Chico at Wedbush, which represents a 69.6% increase from the current price of $21.23.
What is the overall DNTH consensus from analysts for Dianthus Therapeutics Inc.?
The overall analyst consensus for DNTH is bullish. Out of 19 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $52.00.
How accurate are DNTH stock price projections?
Stock price projections, including those for Dianthus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.